ALOPRIM Rx

Select the drug indication to add to your list

ALOPRIM

Hyperuricemia
Miscellaneous urogenital disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Allopurinol (as sodium) 500mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free.

Company:

Mylan Inc.

Select therapeutic use:

Indications for ALOPRIM:

Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.

Adult:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; 3–10mL/min: 100mg/dose. <3mL/min: 100mg/day and extend dosing interval (see literature).

Children:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day. Renal impairment: CrCl 10–20mL/min: 200mg/day; CrCl 3–10mL/min: 100mg/day; CrCl <3mL/min: 100mg/day and extend dosing interval; see literature.

Contraindications:

Asymptomatic hyperuricemia.

Warnings/Precautions:

Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Discontinue if rash occurs. Monitor blood counts, renal, and hepatic function for first few months of therapy. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Potentiates oral anticoagulants, hypoglycemics, cyclosporine, theophylline. Antagonized by uricosurics. Monitor renal function with thiazides. Reduce concomitant azathioprine, mercaptopurine doses.

Pharmacological Class:

Xanthine oxidase inhibitor.

Adverse Reactions:

Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, blood dyscrasias, toxic skin reactions, renal failure.

How Supplied:

Vial—1

Indications for ALOPRIM:

Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.

Adult:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; 3–10mL/min: 100mg/dose. <3mL/min: 100mg/day and extend dosing interval (see literature).

Children:

Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day. Renal impairment: CrCl 10–20mL/min: 200mg/day; CrCl 3–10mL/min: 100mg/day; CrCl <3mL/min: 100mg/day and extend dosing interval; see literature.

Contraindications:

Asymptomatic hyperuricemia.

Warnings/Precautions:

Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Discontinue if rash occurs. Monitor blood counts, renal, and hepatic function for first few months of therapy. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Potentiates oral anticoagulants, hypoglycemics, cyclosporine, theophylline. Antagonized by uricosurics. Monitor renal function with thiazides. Reduce concomitant azathioprine, mercaptopurine doses.

Pharmacological Class:

Xanthine oxidase inhibitor.

Adverse Reactions:

Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, blood dyscrasias, toxic skin reactions, renal failure.

How Supplied:

Vial—1